Ionis Pharmaceuticals (IONS) Q2 2026 Earnings
As seen on the 24/7 Wall St. homepage on July 29, 2026.
Q2 2026
EPS
-$0.69
est -$0.88
+21.4%
Revenue
$268M
est $190M
+41.0%
Ionis beat revenue estimates by 41% on blockbuster new medicine launches and accelerating royalty income, while losses narrowed sharply despite the absence of a $280M one-time payment that juiced last year's quarter; DAWNZERA and TRYNGOLZA are ramping fast enough that management reaffirmed its path to cash-flow breakeven by 2028.
Mentioned: IONS